BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

Core Insights - BriaCell Therapeutics Corp. is expanding its pivotal Phase 3 clinical study by adding two major cancer centers, Los Angeles Cancer Network and Smilow Cancer Hospital, which will increase patient enrollment capabilities [1][7] - The study is focused on evaluating BriaCell's lead candidate, Bria-IMT™, in combination with an immune checkpoint inhibitor for advanced metastatic breast cancer [2][3] - The company anticipates completing patient enrollment by late 2025 or early 2026, with top line data potentially available in the first half of 2026 [1][3] Clinical Study Details - The Phase 3 study aims to compare overall survival (OS) in patients treated with the Bria-IMT combination regimen against those receiving physician's choice, with 144 patient events (deaths) required for interim data analysis [3] - Positive results from this study could lead to full approval and marketing authorization for Bria-IMT in metastatic breast cancer patients [3] - The Bria-IMT combination regimen has received FDA Fast Track designation, indicating its potential significance in treating this patient population [3] Clinical Site Expansion - With the addition of the two cancer centers, BriaCell's Phase 3 study now has a total of 58 active clinical sites across 15 states [7] - The expanded network includes notable institutions such as the University of Arizona and Northwestern University, enhancing patient access to the study [7]